Commentary
Open Access
Should Canadian patients look forward to aducanumab for Alzheimer disease?
Jennifer A. Watt, Roger Marple, Brenda Hemmelgarn and Sharon E. Straus
CMAJ September 13, 2021 193 (36) E1430-E1431; DOI: https://doi.org/10.1503/cmaj.211134
Jennifer A. Watt
Knowledge Translation Program (Watt, Straus), Li Ka Shing Knowledge Institute, St. Michael’s Hospital; Division of Geriatric Medicine, Department of Medicine (Watt, Straus), University of Toronto, Toronto, Ont.; Patient partner (Marple), Medicine Hat, Alta.; Faculty of Medicine and Dentistry (Hemmelgarn), University of Alberta, Edmonton, Alta.; Institute of Health Policy, Management and Evaluation (Straus), Dalla Lana School of Public Health, University of Toronto, Toronto, Ont.
MD PhDRoger Marple
Knowledge Translation Program (Watt, Straus), Li Ka Shing Knowledge Institute, St. Michael’s Hospital; Division of Geriatric Medicine, Department of Medicine (Watt, Straus), University of Toronto, Toronto, Ont.; Patient partner (Marple), Medicine Hat, Alta.; Faculty of Medicine and Dentistry (Hemmelgarn), University of Alberta, Edmonton, Alta.; Institute of Health Policy, Management and Evaluation (Straus), Dalla Lana School of Public Health, University of Toronto, Toronto, Ont.
Brenda Hemmelgarn
Knowledge Translation Program (Watt, Straus), Li Ka Shing Knowledge Institute, St. Michael’s Hospital; Division of Geriatric Medicine, Department of Medicine (Watt, Straus), University of Toronto, Toronto, Ont.; Patient partner (Marple), Medicine Hat, Alta.; Faculty of Medicine and Dentistry (Hemmelgarn), University of Alberta, Edmonton, Alta.; Institute of Health Policy, Management and Evaluation (Straus), Dalla Lana School of Public Health, University of Toronto, Toronto, Ont.
MD PhDSharon E. Straus
Knowledge Translation Program (Watt, Straus), Li Ka Shing Knowledge Institute, St. Michael’s Hospital; Division of Geriatric Medicine, Department of Medicine (Watt, Straus), University of Toronto, Toronto, Ont.; Patient partner (Marple), Medicine Hat, Alta.; Faculty of Medicine and Dentistry (Hemmelgarn), University of Alberta, Edmonton, Alta.; Institute of Health Policy, Management and Evaluation (Straus), Dalla Lana School of Public Health, University of Toronto, Toronto, Ont.
MD MScIn this issue
Article tools
Should Canadian patients look forward to aducanumab for Alzheimer disease?
Jennifer A. Watt, Roger Marple, Brenda Hemmelgarn, Sharon E. Straus
CMAJ Sep 2021, 193 (36) E1430-E1431; DOI: 10.1503/cmaj.211134
Related Articles
Cited By...
- Medicaments modificateurs de la maladie dAlzheimer: implications pour la population canadienne
- Disease-modifying drugs for Alzheimer disease: implications for people in Canada
- Defis poses par les nouveaux traitements de la maladie dAlzheimer: Lapprobation acceleree de laducanumab aux Etats-Unis souleve des questions
- Challenges with new treatments for Alzheimer disease: Accelerated approval of aducanumab in the United States raises questions